ArticleImmunotherapy2025

5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.

Stephen V Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.